Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Rachel Soon, 04 Aug 2017

Investment in health crisis response systems during non-pandemic periods is crucial to combating the next inevitable flu pandemic, according to a government representative.

30 Apr 2016
New drug applications approved by US FDA as of 16 - 30 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
15 Jan 2017
New drug applications approved by US FDA as of 1 - 15 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New Product Highlight - Flutiform

22 Jun 2015
FLUTIFORM®– Fluticasone propionate and Formoterol fumarate Inhalation 50 mcg/5 mcg, 125 mcg/5 mcg and 250 mcg/10 mcg  
• flutiform® combines the ICS and LABA that doctors prefer:1,2
     - Well-tolerated and potent anti-inflammatory effects of fluticasone1-5
     - Fast onset and sustained bronchodilatory action of formoterol1-5
• flutiform® delivers a consistently high fine particle fraction across flow rates.6

References:
1. Price D, Bousquet J. Real-world perceptions of inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma. Resp Med 2012; 106 (S1): S4-S8.
2.
Thomas M, Haughney J, Price D. Physicians’ attitudes towards combination therapy with inhaled corticosteroids and long-acting β2-agonist: an observational study in UK specialist care. Prag Obs Res 2011; 2: 25-31.
3. Flutiform® Approved Prescribing Information/Data Sheet.
4. Bodzenta-Lukaszyk A et al. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatmentof asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 2011; 11: 28-37.
5. Aalbers R et al. Onset ofbronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. Adv Ther 2012; 29 (11):958-969.
6.
Johal B, Howald M, Fischer M, Marshall J. Comparison of the fine particle fraction of fluticasone propionate/formoterol fumarate combination with other combination products. Poster presented at the European Respiratory Society (ERS) 22nd Annual Congress, 1–5 September 2012, Vienna,Austria.

Further information available in Section 3b, New in This Issue and mims.com.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Rachel Soon, 04 Aug 2017

Investment in health crisis response systems during non-pandemic periods is crucial to combating the next inevitable flu pandemic, according to a government representative.

30 Apr 2016
New drug applications approved by US FDA as of 16 - 30 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
15 Jan 2017
New drug applications approved by US FDA as of 1 - 15 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.